A Dose Escalation Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Hemay102 in Patients With Advanced Solid Tumors
This trial was a single-center, open-label, dose-increasing Phase I clinical study with subjects enrolled in patients with advanced solid tumors who failed standard treatment or who were unable to receive effective treatment. The trial is divided into two stages: dose escalation and dose extension.
评价Hemay102在晚期实体瘤患者中安全性、耐受性、药代动力学特征和初步抗肿瘤疗效的剂量递增Ⅰ期临床研究
主要目的:评价Hemay102在晚期实体瘤患者中的安全性和耐受性。 次要目的:评价Hemay102在晚期实体瘤患者中的药代动力学特征;初步评价Hemay102的抗肿瘤疗效。
100 项与 Hemay-102 相关的专利(医药)